BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
 
ProtoCOL at Major Vaccine Manufacturers Makes Testing Flu Vaccines Twenty Times Faster

8th November 2004 Cambridge, UK: Synbiosis, a world-leading manufacturer of automated reaction zone measurement systems is pleased to announce that major international vaccine suppliers are using the ProtoCOL system to improve the speed and accuracy of testing flu vaccines.

The vaccine suppliers use Synbiosis’s GLP compliant ProtoCOL, with its integrated CCD camera and software, to determine the size of reaction zones on single radial immunodiffusion (SRD) assay plates. This is a standard test to determine the potency of flu and other vaccines.

A Research Assistant at one vaccine manufacturer commented: “The ProtoCOL is excellent for SRD assays. It allows us to alter the contrast manually and this is useful because with a Coomassie blue stain the depth of colour can differ across the SRD plate. Therefore, changing the contrast can mean the difference between seeing and measuring a diffuse zone or not. Also since the system does the reading we have time to inspect each plate to find wells that are not perfectly circular.”

“Before we had a ProtoCOL we used a computerised system to mark one well at a time with a mouse and reading each plate was a 15-20 minute process. With the ProtoCOL we overlay the template and have a 16-well plate measured in less than a minute. We are so confident in the ProtoCOL that we are going to use it in a stability study of a new flu vaccine to read 200-300 SRD plates a week. The increased capacity it provides will help complete this work in a fraction of the time it would have taken,” the Research Assistant added.

Simon Johns, Divisional Manager for Synbiosis stated: “The ProtoCOL system is fast becoming the international standard for automating SRD assays and it is now being applied widely. The fact that the ProtoCOL at leading vaccine manufacturers increases throughput by twenty times is a great endorsement of its capabilities and shows pharmaceutical companies developing vaccines or antibiotics how much it could boost their productivity.”
 

-Ends-

For Further Information Contact:
Jayne Arthur, Synbiosis, Beacon House, Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727125 Fax +44(0) 1223-727101
Email: jayne.arthur@synbiosis.com  Web site: www.synbiosis.com  

Editor Contact:
Dr Sue Pearson, PO Box 170, Hitchin, Hertfordshire SG5 3GD, UK.
Tel/Fax +44(0) 1462-635327 Email: sue6.pearson@ntlworld.com

Note to Editors

About Synbiosis

Synbiosis is a world-leading supplier of automatic colony counting and zone measurement systems. Synbiosis’s ProtoCOL and åCOLyte systems are used in food, pharmaceutical, environmental and research laboratories world-wide. Synbiosis uses established distribution channels to market its products internationally.

Synbiosis, founded in 1998 is a division of the Synoptics Group based in Cambridge UK. The Group’s other divisions, Syncroscopy and Syngene, specialise in digital imaging solutions for microscopy and molecular biology applications respectively. Synoptics currently employs 55 people in its UK and US subsidiary operation and has profitable revenue of almost $10 million, which continues to grow rapidly.
 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.